{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:37:41Z","timestamp":1722515861408},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00059-016-4422-8","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T09:07:36Z","timestamp":1460711256000},"page":"697-705","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Kardiovaskul\u00e4res Risiko unter Androgendeprivationstherapie zur\u00a0Behandlung\u00a0des\u00a0hormonabh\u00e4ngigen\u00a0Prostatakarzinoms"],"prefix":"10.1007","volume":"41","author":[{"given":"C.","family":"Tsch\u00f6pe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Kherad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Spillmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Krackhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"issue":"1","key":"4422_CR1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.09.008","volume":"86","author":"V Conteduca","year":"2013","unstructured":"Conteduca V et\u00a0al (2013) The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol 86(1):42\u201351","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"4422_CR2","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2007-2595","volume":"93","author":"S Shahani","year":"2008","unstructured":"Shahani S, Braga-Basaria M, Basaria S (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93(6):2042\u20132049","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"4422_CR3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/ijc.23736","volume":"123","author":"JD Otten","year":"2008","unstructured":"Otten JD et al (2008) Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975\u20132006. Int J Cancer 123(8):1929\u20131934","journal-title":"Int J Cancer"},{"issue":"2","key":"4422_CR4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR et\u00a0al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J\u00a0Clin Endocrinol Metab 87(2):599\u2013603","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4422_CR5","first-page":"332","volume":"35","author":"L Collins","year":"2012","unstructured":"Collins L et\u00a0al (2012) Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care. J\u00a0Endocrinol Invest 35(3):332\u2013339","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"4422_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clgc.2014.07.009","volume":"12","author":"S Edelman","year":"2014","unstructured":"Edelman S et\u00a0al (2014) The Effects of Androgen Deprivation Therapy on Cardiac Function and Heart Failure: Implications for Management of Prostate Cancer. Clin Genitourin Cancer 12(6):399\u2013407","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"4422_CR7","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.104.523217","volume":"112","author":"CX Bai","year":"2005","unstructured":"Bai CX et\u00a0al (2005) Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 112(12):1701\u20131710","journal-title":"Circulation"},{"issue":"1","key":"4422_CR8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cardiores.2004.09.012","volume":"65","author":"J Brouillette","year":"2005","unstructured":"Brouillette J et\u00a0al (2005) Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc Res 65(1):148\u2013157","journal-title":"Cardiovasc Res"},{"issue":"16","key":"4422_CR9","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.0000033596.21845.D8","volume":"106","author":"TV Pham","year":"2002","unstructured":"Pham TV et\u00a0al (2002) Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation 106(16):2132\u20132136","journal-title":"Circulation"},{"issue":"4","key":"4422_CR10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjp.0707624","volume":"153","author":"S Tsang","year":"2008","unstructured":"Tsang S et al (2008) Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation. Br J Pharmacol 153(4):693\u2013709","journal-title":"Br J Pharmacol"},{"issue":"4","key":"4422_CR11","doi-asserted-by":"crossref","first-page":"e000271","DOI":"10.1161\/JAHA.113.000271","volume":"2","author":"MJ Herring","year":"2013","unstructured":"Herring MJ et\u00a0al (2013) Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J\u00a0Am Heart Assoc 2(4):e000271","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"4422_CR12","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1161\/01.CIR.0000146900.84943.E0","volume":"110","author":"F Er","year":"2004","unstructured":"Er F et al (2004) Testosterone induces cytoprotection by activating ATP-sensitive K+ channels in the cardiac mitochondrial inner membrane. Circulation 110(19):3100\u20133107","journal-title":"Circulation"},{"issue":"11","key":"4422_CR13","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1210\/en.2010-0663","volume":"151","author":"J Bourghardt","year":"2010","unstructured":"Bourghardt J et al (2010) Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology 151(11):5428\u20135437","journal-title":"Endocrinology"},{"issue":"3","key":"4422_CR14","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/JOE-12-0582","volume":"217","author":"DM Kelly","year":"2013","unstructured":"Kelly DM, Jones TH (2013) Testosterone: a vascular hormone in health and disease. J\u00a0Endocrinol 217(3):R47\u201371","journal-title":"J Endocrinol"},{"issue":"5","key":"4422_CR15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0006-291X(02)02038-7","volume":"296","author":"C Langer","year":"2002","unstructured":"Langer C et al (2002) Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 296(5):1051\u20131057","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"4422_CR16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.urolonc.2015.05.030","volume":"33","author":"A Tivesten","year":"2015","unstructured":"Tivesten A et\u00a0al (2015) Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. Urol Oncol 33(11):464","journal-title":"Urol Oncol"},{"issue":"3","key":"4422_CR17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1095\/biolreprod.107.063545","volume":"78","author":"JA Rettew","year":"2008","unstructured":"Rettew JA, Huet-Hudson YM, Marriott I (2008) Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod 78(3):432\u2013437","journal-title":"Biol Reprod"},{"issue":"3","key":"4422_CR18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.phrs.2004.03.010","volume":"50","author":"EM Ammar","year":"2004","unstructured":"Ammar EM, Said SA, Hassan MS (2004) Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. Pharmacol Res 50(3):253\u2013259","journal-title":"Pharmacol Res"},{"issue":"5","key":"4422_CR19","doi-asserted-by":"crossref","first-page":"H2043","DOI":"10.1152\/ajpheart.01121.2005","volume":"290","author":"MA Cavasin","year":"2006","unstructured":"Cavasin MA et\u00a0al (2006) Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol 290(5):H2043\u201350","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"27","key":"4422_CR20","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J\u00a0Clin Oncol 24(27):4448\u20134456","journal-title":"J Clin Oncol"},{"issue":"3","key":"4422_CR21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC et\u00a0al (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65(3):565\u2013573","journal-title":"Eur Urol"},{"issue":"11","key":"4422_CR22","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11):2388\u20132399","journal-title":"Cancer"},{"issue":"12","key":"4422_CR23","doi-asserted-by":"crossref","first-page":"M1103","DOI":"10.1093\/gerona\/58.12.M1103","volume":"58","author":"S Bhasin","year":"2003","unstructured":"Bhasin S et\u00a0al (2003) The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J\u00a0Gerontol A Biol Sci Med Sci 58(12):M1103\u201310","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"4422_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2164\/jandrol.108.005751","volume":"30","author":"AM Traish","year":"2009","unstructured":"Traish AM, Saad F, Guay A (2009) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J\u00a0Androl 30(1):23\u201332","journal-title":"J Androl"},{"issue":"2","key":"4422_CR25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","volume":"71","author":"MR Smith","year":"2008","unstructured":"Smith MR et\u00a0al (2008) Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71(2):318\u2013322","journal-title":"Urology"},{"issue":"4","key":"4422_CR26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"MR Smith","year":"2006","unstructured":"Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J\u00a0Clin Endocrinol Metab 91(4):1305\u20131308","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"4422_CR27","first-page":"687","volume":"4","author":"LK Harle","year":"2006","unstructured":"Harle LK et al (2006) Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 4(9):687\u2013696","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"4422_CR28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","volume":"104","author":"F Dockery","year":"2003","unstructured":"Dockery F et\u00a0al (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104(2):195\u2013201","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"4422_CR29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0022-5347(01)67239-2","volume":"154","author":"LM Eri","year":"1995","unstructured":"Eri LM, Urdal P, Bechensteen AG (1995) Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 154(1):100\u2013104","journal-title":"J Urol"},{"issue":"10","key":"4422_CR30","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.23440","volume":"112","author":"MR Smith","year":"2008","unstructured":"Smith MR et al (2008) Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 112(10):2188\u20132194","journal-title":"Cancer"},{"issue":"4","key":"4422_CR31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2826.2009.01842.x","volume":"21","author":"DC Skinner","year":"2009","unstructured":"Skinner DC et al (2009) Effects of gonadotrophin-releasing hormone outside the hypothalamic-pituitary-reproductive axis. J Neuroendocrinol 21(4):282\u2013292","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"4422_CR32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2826.2011.02119.x","volume":"23","author":"F Dong","year":"2011","unstructured":"Dong F et al (2011) The heart: a novel gonadotrophin-releasing hormone target. J Neuroendocrinol 23(5):456\u2013463","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"4422_CR33","first-page":"743","volume":"84","author":"HF Chen","year":"1999","unstructured":"Chen HF et al (1999) Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 84(2):743\u2013750","journal-title":"J Clin Endocrinol Metab"},{"key":"4422_CR34","volume-title":"Treatment with an LRHR agonist, but not the LHRH antagonist degarelix, induces atherosclerotic plaque instability in ApoE-\/- mice","author":"A Knutsson","year":"2015","unstructured":"Knutsson A et al (2015) Treatment with an LRHR agonist, but not the LHRH antagonist degarelix, induces atherosclerotic plaque instability in ApoE-\/- mice in EAU 2015, Poster 5592015: Madrid"},{"key":"4422_CR35","unstructured":"Fachinformation, FIRMAGON 80\u202fmg Pulver und L\u00f6sungsmittel zur Herstellung einer Injektionsl\u00f6sung. Ferring GmbH. 011697-7981 \u2013 Stand der Information: Oktober 2014"},{"issue":"19","key":"4422_CR36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/jnci\/djs376","volume":"104","author":"NL Keating","year":"2012","unstructured":"Keating NL et\u00a0al (2012) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J\u00a0Natl Cancer Inst 104(19):1518\u20131523","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"4422_CR37","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","volume":"28","author":"M Hemelrijck Van","year":"2010","unstructured":"Van Hemelrijck M et al (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28(21):3448\u20133456","journal-title":"J Clin Oncol"},{"issue":"4","key":"4422_CR38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","volume":"65","author":"CG Jespersen","year":"2014","unstructured":"Jespersen CG, Norgaard M, Borre M (2014) Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 65(4):704\u2013709","journal-title":"Eur Urol"},{"issue":"20","key":"4422_CR39","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK et\u00a0al (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J\u00a0Natl Cancer Inst 99(20):1516\u20131524","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"4422_CR40","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS et\u00a0al (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110(7):1493\u20131500","journal-title":"Cancer"},{"issue":"6","key":"4422_CR41","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","volume":"61","author":"JC Hu","year":"2012","unstructured":"Hu JC et al (2012) Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol 61(6):1119\u20131128","journal-title":"Eur Urol"},{"issue":"6b","key":"4422_CR42","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1111\/bju.12732","volume":"114","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia G et al (2014) The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int 114(6b):E82\u20139","journal-title":"BJU Int"},{"issue":"21","key":"4422_CR43","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","volume":"27","author":"SM Alibhai","year":"2009","unstructured":"Alibhai SM et\u00a0al (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J\u00a0Clin Oncol 27(21):3452\u20133458","journal-title":"J Clin Oncol"},{"key":"4422_CR44","doi-asserted-by":"publisher","first-page":"\u25a0","DOI":"10.1111\/bju.13203","volume":"\u25a0","author":"M Schmid","year":"2015","unstructured":"Schmid M et al (2015) Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int : doi:10.1111\/bju.13203","journal-title":"BJU Int"},{"issue":"suppl 7","key":"4422_CR45","doi-asserted-by":"crossref","first-page":"abstr 190","DOI":"10.1200\/jco.2011.29.7_suppl.190","volume":"29","author":"MR Smith","year":"2011","unstructured":"Smith MR et al (2011) Association of baseline risk factors with cardiovascular (CV) events during long-term degarelix therapy in men with prostate cancer. J Clin Oncol 29(suppl 7):abstr 190","journal-title":"J Clin Oncol"},{"issue":"1","key":"4422_CR46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","volume":"27","author":"JA Efstathiou","year":"2009","unstructured":"Efstathiou JA et al (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27(1):92\u201399","journal-title":"J Clin Oncol"},{"issue":"11","key":"4422_CR47","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11(11):1066\u20131073","journal-title":"Lancet Oncol"},{"issue":"1","key":"4422_CR48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000334999","volume":"82","author":"C Wilcox","year":"2012","unstructured":"Wilcox C et\u00a0al (2012) Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncology 82(1):56\u201358","journal-title":"Oncology"},{"issue":"21","key":"4422_CR49","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL et al (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21):2359\u20132366","journal-title":"JAMA"},{"key":"4422_CR50","first-page":"681","volume":"suppl. 2","author":"B Tombal","year":"2013","unstructured":"Tombal B et al (2013) Degarelix versus luteinising hormone-releasing hormone (LHRH) agonists: Safety outcomes from six comparative randomised clinical trials. Eur J Cancer (suppl. 2):681","journal-title":"Eur J Cancer"},{"issue":"17","key":"4422_CR51","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1001283","volume":"363","author":"A Radu","year":"2010","unstructured":"Radu A et al (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363(17):1621\u20131630","journal-title":"N Engl J Med"},{"issue":"10","key":"4422_CR52","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/01.CIR.103.10.1382","volume":"103","author":"H Hanke","year":"2001","unstructured":"Hanke H et\u00a0al (2001) Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103(10):1382\u20131385","journal-title":"Circulation"},{"issue":"7","key":"4422_CR53","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jacc.2003.07.002","volume":"42","author":"MK Ng","year":"2003","unstructured":"Ng MK et al (2003) Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J Am Coll Cardiol 42(7):1306\u20131313","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4422_CR54","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.eururo.2013.12.063","volume":"66","author":"L Klotz","year":"2014","unstructured":"Klotz L et al (2014) Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 66(6):1101\u20131108","journal-title":"Eur Urol"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4422-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-016-4422-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4422-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4422-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:52:45Z","timestamp":1558540365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-016-4422-8"}},"subtitle":["Unterschiede zwischen GnRH-Antagonisten gegen\u00fcber GnRH-Agonisten"],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["4422"],"URL":"https:\/\/doi.org\/10.1007\/s00059-016-4422-8","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]}}}